Literature DB >> 4017167

High-performance liquid chromatographic assay for simultaneous estimation of aminoglutethimide and acetylaminoglutethimide in biological fluids.

A M Adam, I D Bradbrook, H J Rogers.   

Abstract

A simple rapid high-performance liquid chromatographic assay for simultaneous estimation of aminoglutethimide and its acetylated metabolite acetylamidoglutethimide in plasma, saliva, and urine is described. This assay is suitable for pharmacokinetic studies in normal subjects and patients receiving other medication in addition to aminoglutethimide.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4017167     DOI： 10.1007/bf00257533

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  7 in total

1.  Effects of amino-glutethimide on adrenal function in man.

Authors:  L M Fishman; G W Liddle; D P Island; N Fleischer; O Küchel
Journal:  J Clin Endocrinol Metab       Date:  1967-04       Impact factor: 5.958

2.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Authors:  R Cash; A J Brough; M N Cohen; P S Satoh
Journal:  J Clin Endocrinol Metab       Date:  1967-09       Impact factor: 5.958

3.  Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance.

Authors:  F T Murray; S Santner; E Samojlik; R J Santen
Journal:  J Clin Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.126

4.  In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.

Authors:  R J Santen; S J Santner; N Tilsen-Mallett; H R Rosen; E Samojlik; J D Veldhuis
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

5.  Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.

Authors:  R J Santen; T J Worgul; A Lipton; H Harvey; A Boucher; E Samojlik; S A Wells
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

6.  Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents.

Authors:  T A Thompson; J D Vermeulen; W E Wagner; A R Le Sher
Journal:  J Pharm Sci       Date:  1981-09       Impact factor: 3.534

7.  Polymorphically acetylated aminoglutethimide in humans.

Authors:  R C Coombes; A B Foster; S J Harland; M Jarman; E C Nice
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640
  7 in total
  4 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.

Authors:  A A Miller; B E Miller; K Höffken; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.